TY - JOUR
T1 - Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML
T2 - Widening the Yellow Brick Road
AU - Adrianzen-Herrera, Diego A.
AU - Shastri, Aditi
N1 - Publisher Copyright:
©2022 American Association for Cancer Research.
PY - 2022/10/3
Y1 - 2022/10/3
N2 - A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
AB - A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
UR - http://www.scopus.com/inward/record.url?scp=85139535531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139535531&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-1881
DO - 10.1158/1078-0432.CCR-22-1881
M3 - Editorial
C2 - 35876635
AN - SCOPUS:85139535531
SN - 1078-0432
VL - 28
SP - 4167
EP - 4170
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 19
ER -
